Shares of Jubilant Pharmova Ltd surged 4% on 13 June after the corporate introduced that its board had approved the sale and switch of its energetic pharmaceutical ingredient (API) enterprise to its wholly-owned subsidiary, Jubilant Biosys Ltd, on a stoop foundation.
In its regulatory submitting, the corporate stated, “the board of administrators of Jubilant Pharmova in its assembly held at this time, i.e., 12 June 2025, at 03:00 pm and concluded at 03:28 pm, inter alia, thought of and authorized sale and switch of the Lively Pharmaceutical Elements (API) enterprise of the corporate (Enterprise) on a stoop sale foundation to Jubilant Biosys Restricted (JBL), a wholly-owned subsidiary firm, engaged in offering drug discovery providers to world Pharmaceutical and Biotech corporations.”
In FY25, the API phase generated Rs 609 crore or 8.35% of the corporate’s complete income. As of 31 March 2025, its internet value was Rs 666.5 crore, accounting for 10.68% of the corporate’s consolidated internet value.
The switch is deliberate to be accomplished by 1 September 2025, topic to the phrases specified within the enterprise switch settlement. The consideration for the switch shall be based mostly on the e book worth of property and liabilities as of the appointed date. The switch will probably be accomplished principally via the issuance of shares.
Jubilant Biosys is a very owned subsidiary. Therefore, the acquisition qualifies as a associated get together transaction. Nevertheless, the company said that the transaction is being carried out at arm’s size.
The sale is going down exterior of a Scheme of Association, and compliance with Regulation 37A of the SEBI Itemizing Rules will not be essential as a result of Jubilant Biosys’ accounts are consolidated with these of Jubilant Pharmova.
At 12:36 pm, the shares of Jubilant Pharmova had been buying and selling 2.34% decrease at Rs 1,099.30 on NSE.
Uncover the subsequent massive funding! Unicorn Indicators’ IPO screener helps you establish promising preliminary public choices. Obtain Unicorn Indicators and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
